ISM5411, A NOVEL GUT-RESTRICTED PHD1/2 INHIBITOR FOR INFLAMMATORY BOWEL DISEASE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIRST-IN-HUMAN PHASE I STUDY TO EVALUATE SAFETY, TOLERABILITY AND PK PROFILES